1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Novartis Looks To Extend Top-Selling Cosentyx Into Juvenile Arthritis

Primary Endpoint Met In Phase III JUNIPERA Study

 
• By John Davis

Top-line results from the Phase III JUNIPERA study of Novartis’s IL17A-targeting anti-inflammatory Cosentyx support its use in juvenile idiopathic arthritis, and the company intends to move quickly to enter the marketplace in pediatric patients with two subtypes of the condition.  

juvenile arthritis
• Source: Alamy

Novartis AG is busily extending the reach of its top-selling anti-inflammatory Cosentyx into pediatric indications and expects to make regulatory submissions “within weeks”, after obtaining positive results from the Phase III JUNIPERA study in two subtypes of juvenile idiopathic arthritis. 

Clinical findings from the JUNIPERA study of Cosentyx (secukinumab) in pediatric patients with juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?